Yersinia Diagnostics Market by Types (Stool Culture, Colonoscopy, Radioimmunoassay, Tube Agglutination, ELISA, CT Scan, and Ultrasonography), Technology (Immunoassay, PCR, Monoclonal Antibodies, DNA Probes, and Others), End-users (Ambulatory Centers and Hospitals), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

The global yersinia diagnostic market size is estimated to expand at a significant rate during the forecast period, 2021–2028. The growth of the market is attributed to the growing demand for usage of novel molecular diagnostic tools.

Yersinia, a gram-positive rod-shaped of bacteria, belongs to the enterobacteriaceae family and all pathogenic bacteria are Yersinia pestis. It triggers bubonic plague and is infective by mice and fleas. The bacteria are transmitted through several modes of such as infective flea to human, human to human transmission, and rodent to human. yersinia pestis causes terminal ileitis, acute diarrhea, mesenteric lymphadenitis, and enterocolitis. Dyspnea, swelling of lymph nodes, fever, hemoptysis, and chest pain are among some of the symptoms caused by yersinia infection. Patients sometimes also develop erythmanodosum, which results in painful red or purple lesions on the legs. These lesions are visible after two to 20 days post the onset of fever and abdominal pain.

Men are affected three times more than women by the infections, but post-infection complications of arthritis and nodosum are more common in women. It is one of the common causes of bacterial gastrointestinal infection in children. Yersinia infection in patients is confirmed by performing laboratory diagnosis immediate after serological tests to support the associated syndromes. Some of the treatments for Yersinia infection include cephalosporins, aminoglycosides, tetracyclines, fluoroquinolones, and trimethoprim-sulfamethoxazole.

The significant growth of the yersinia diagnostic market is closely related to the outbreak of the COVID-19 pandemic as the pandemic has created opportunity to the manufacturers to develop and produce advanced medical diagnostic kits supplies to control the diseases. Patients having chronic diseases are at a greater risk of exposing to the virus and the mortality rate among the aging patients are reported to be high globally.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing health-consciousness among people and rise in adoption of diagnostic tools present as key factors for the market growth.
• Rising number of patients worldwide and the growing prevalence rate of yersiniosis in the advanced countries are expected to expand the market in the coming years.
• Development of innovative diagnostic products and technological advancement in the area of diagnostics market are projected to fuel the market growth during the forecast period.
• Issues regarding low accuracy in the testing outcomes and less-skilled technicians handling the diagnostic devices are major challenges that can hamper the market growth.
• Ongoing R&D programs to improve the functionality and accuracy in the testing devices from several medical device manufacturing companies are projected to offer lucrative opportunities for the market growth in the long run.

Scope of the Report

The report on the global yersinia diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Radioimmunoassay segment is anticipated to hold a key market share

On the basis of types, the global Yersinia diagnostics market is divided into stool culture, colonoscopy, radioimmunoassay, tube agglutination, ELISA, CT scan, and ultrasonography. The radioimmunoassay segment is anticipated to hold a key market share during the forecast period owing to wide prevalence of the diagnostic method and availability of advanced diagnostic techniques for detecting the disease. 

PCR segment is expected to grow at a rapid pace

Based on technology, the market is segregated into immunoassay, PCR, monoclonal antibodies, DNA probes, and others. The PCR segment is expected to grow at a rapid pace during the forecast period, attributing to technological advancement in the area of research & development and genetic engineering. To detect pathogens, monoclonal antibodies are used in many methods, including PCR. A multiplex real-time polymerase chain reaction (RT-PCR) assay was developed for the determination of Yersinia pseudotuberculosis and Yersinia pestis, making the PCR test more accurate and faster. The increasing demand for usage of high-throughput PCR technology to identify Yersinia is projected to boost the market. In addition to that, adoption of advanced technology in this category are anticipated to upsurge the overall market growth. Plasmonic PCR, a cost- effective and faster procedure for detecting infections and pathogen is one of the examples of advanced technology in this segment.

Hospitals segment is projected to expand considerably in the market

On the basis of end-users, the global yersinia diagnostic market is divided into ambulatory center and hospitals. The hospitals segment is projected to expand considerably in the market in the coming years due to increase in demand for diagnostic tests for in-patients and premium chargers applied for test in hospitals. The hospitals segment represented over 45.4% of the global market share in 2020 and is expected to register robust growth in the coming years with wide availability of advanced diagnostic devices and presence of high-skilled medical staff including doctors, nurses, and technicians in hospitals.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the rise in the cases of the infectious diseases. Additionally, the increasing geriatric population is anticipated to fuel the market growth in coming years. On the other hand, the market of Asia Pacific is projected to register a high CAGR during the forecast period owing to increasing government initiatives through investments in healthcare infrastructure development in the region.

Segments

Segments Covered in the Report
The global yersinia diagnostic market has been segmented on the basis of
Types

• Stool Culture
• Colonoscopy
• Radioimmunoassay
• Tube Agglutination
• ELISA
• CT Scan
• Ultrasonography

Technology

• Immunoassay
• PCR
• Monoclonal Antibodies
• DNA Probes
• Others

End-users

• Ambulatory Centers
• Hospitals

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Abbott Laboratories
• Hologic Inc
• F. Hoffmann La-Roche
• Becton, Dickinson and Company
• Danaher Corporation
• Bio-Rad Laboratories
• Thermo Fisher Scientific Inc.

Competitive Landscape

The major players competing in the global yersinia diagnostic market are Abbott Laboratories; Danaher Corporation; Hologic Inc; F. Hoffmann La-Roche; Bio-Rad Laboratories; Thermo Fisher Scientific Inc.; and Becton, Dickinson and Company.

These companies are implementing strategies such as technological advancements, innovative solution, new developed product launches, research initiatives, merger & acquisitions, and regional expansions to secure their advantageous position in the yersinia diagnostics market.